Pharmaceutical companies, lea by Johnson & Johnson, have begun testing drugs aimed at treating premature sexual ejaculation.
Johnson's dapoxetine has been under review by the Food and Drug Administration for six months, and industry experts said the drug might soon become the first approved for the condition, which is estimated to affect 15 percent to 30 percent of American men, the Wall Street Journal reported Tuesday.
A major study presented during the American Urological Association annual meeting in San Antonio suggested dapoxetine could help men delay &to=http:// english.pravda.ru/fun/2002/08/21/34936.html ' target=_blank>orgasm, the Journal said.
The companies have been encouraged by the $2.5 billion-a-year erectile dysfunction industry. The companies, experts say, are hoping the new treatments will, as did Viagra, represent the next generation of lifestyle drugs, reports the Washington Times.
According to Reuters, only about 20 to 25 percent of the men's partners felt satisfied by sex before the men took the drug but this doubled to 47 percent after the men took the highest dose.
The trial was a phase III clinical trial of 2,614 men, designed to be the last test before seeking U.S. Food and Drug Administration approval.
It is a drug called a serotonin transporter &to=http:// english.pravda.ru/society/2002/03/22/27142.html ' target=_blank>inhibitor.